(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 18.23% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.43%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Grail's revenue in 2026 is $166,604,000.On average, 14 Wall Street analysts forecast GRAL's revenue for 2026 to be $7,716,857,409, with the lowest GRAL revenue forecast at $7,340,524,037, and the highest GRAL revenue forecast at $8,025,747,524. On average, 14 Wall Street analysts forecast GRAL's revenue for 2027 to be $9,662,820,170, with the lowest GRAL revenue forecast at $8,715,467,227, and the highest GRAL revenue forecast at $11,812,011,943.
In 2028, GRAL is forecast to generate $12,535,453,275 in revenue, with the lowest revenue forecast at $10,531,039,692 and the highest revenue forecast at $16,537,985,737.